Scott M. Lippman, MD, is Director of Moores Cancer Center (PI NCI-designated Comprehensive P30), Distinguished Professor of Medicine, Senior Associate Dean and Associate Vice Chancellor, Cancer Research and Care, University of California, San Diego School of Medicine; holds the Chugai Pharmaceutical endowed Chair; and is an adjunct professor at the Salk Institute, the Sanford Burnham Prebys Medical Discovery Institute and MD Anderson Cancer Center (MDACC). Before joining UC San Diego Health, he was chair of the Department of Thoracic/Head and Neck Medical Oncology at MDACC. He received his medical degree from The Johns Hopkins University School of Medicine, and is triple-board-certified in internal medicine, hematology and medical oncology.
Dr. Lippman has led translational research as PI of high-impact investigator-initiated and definitive trials in the lung, head and neck (HN) and prostate, including the first precision medicine trials in HN prevention and lung therapy. He is well-respected clinically, with recognition in “Top Doctor” listings, including U.S. News & World Report. His research centers on precancers, two tiers—copy-number and immune—and he has published in NEJM, JAMA/JAMA Oncol, Cancer Cell, PNAS, Nature family (e.g., Nature, Nat Med, NCB, Nat Genet), JNCI, The Lancet/Lancet Oncol, Cancer Discov and chapters in major medical textbooks (e.g., many editions of Cecil Medicine, Cancer Medicine, The Molecular Basis of Cancer, Cancer: Principles & Practice of Oncology). Dr. Lippman has been funded as PI by the NCI continuously since 1990 (including 2 P01s, SPORE; current NCI R01), by an SU2C Dream Team award, and has received numerous prevention and team-science awards, including from the ACS, ASCO, MDACC, and AACR. He has chaired ASCO and AACR Prevention Committees; national prevention conferences, symposia, and NCI PCGA and related Think Tanks; and served on NCI Cooperative Group (SWOG Scientific Advisory Board, committee chair), and Clinical Trials and Translational Research Advisory Committee (CTAC). Dr. Lippman has chaired NIH CDP Study Section; served as member of the FDA ODAC, NCI Subcomm A; and been elected to the AACR, AACI, and NCCN Board of Directors and to the prestigious physician-scientist society, Association of American Physicians (AAP) and the National Academies of Sciences, Engineering, and Medicine National Cancer Policy Forum.
